The role of tumour–stromal interactions in modifying drug response: challenges and opportunities

Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?

(2012) Tomoya Yokota   Anti-Cancer Agents in Medicinal Chemistry

Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function

(2012) D. W. McMillin et al.   BLOOD

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma

(2012) R. W. J. Groen et al.   BLOOD

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

(2012) M. Chesi et al.   BLOOD

The metastatic niche and stromal progression

(2012) Jonathan P. Sleeman   CANCER AND METASTASIS REVIEWS

Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

(2012) Taru Muranen et al.   CANCER CELL

Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance

(2012) Elizabeth S. Nakasone et al.   CANCER CELL

Seed, soil and secreted hormones: Potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates

(2012) C. Wilson et al.   CANCER TREATMENT REVIEWS

Current advances in humanized mouse models

(2012) Ryoji Ito et al.   Cellular & Molecular Immunology

Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer

(2012) Eveline M. Dijkgraaf et al.   CURRENT PHARMACEUTICAL DESIGN

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

(2012) Libero Santarpia et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

(2012) Mallika Singh et al.   JOURNAL OF PATHOLOGY

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Modeling and predicting clinical efficacy for drugs targeting the tumor milieu

(2012) Mallika Singh et al.   NATURE BIOTECHNOLOGY

Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia

(2012) Wan Zhang et al.   NATURE CELL BIOLOGY

Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms

(2012) Ayalew Tefferi   NEW ENGLAND JOURNAL OF MEDICINE

Paraneoplastic Thrombocytosis in Ovarian Cancer

(2012) Rebecca L. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bone Marrow Stromal Cells Modulate Mouse ENT1 Activity and Protect Leukemia Cells from Cytarabine Induced Apoptosis

(2012) Patricia Macanas-Pirard et al.   PLoS One

Functional genomics identifies therapeutic targets for MYC-driven cancer

(2012) M. Toyoshima et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

(2012) Hubing Shi et al.   Nature Communications

Translational approaches targeting the p53 pathway for anti-cancer therapy

(2011) Frank Essmann et al.   BRITISH JOURNAL OF PHARMACOLOGY

Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia

(2011) Thomas Schmidt et al.   CANCER CELL

The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment

(2011) Ning Li et al.   CANCER CELL

Bone Marrow Stroma-Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor

(2011) T. Manshouri et al.   CANCER RESEARCH

New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance

(2011) Giuseppe Curigliano   CANCER TREATMENT REVIEWS

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Tumor Metastasis: Molecular Insights and Evolving Paradigms

(2011) Scott Valastyan et al.   CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Immune microenvironments in solid tumors: new targets for therapy

(2011) S. L. Shiao et al.   GENES & DEVELOPMENT

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts

(2011) Y Tabe et al.   LEUKEMIA

Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved  4 Integrin Expression and a Compromised CAM-DR Phenotype

(2011) M. F. Emmons et al.   MOLECULAR CANCER THERAPEUTICS

Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance

(2011) Edward H. Flach et al.   MOLECULAR PHARMACEUTICS

Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment

(2011) Jonathan W. Wojtkowiak et al.   MOLECULAR PHARMACEUTICS

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Histamine restricts cancer: nothing to sneeze at

(2011) Brian Ruffell et al.   NATURE MEDICINE

Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression

(2011) Mina J Bissell et al.   NATURE MEDICINE

Immune parameters affecting the efficacy of chemotherapeutic regimens

(2011) Laurence Zitvogel et al.   Nature Reviews Clinical Oncology

Genomically humanized mice: technologies and promises

(2011) Anny Devoy et al.   NATURE REVIEWS GENETICS

Antibodies in oncology

(2011) Vinochani Pillay et al.   New Biotechnology

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation

(2011) Douglas W. McMillin et al.   PLoS One

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance

(2011) J.-P. Gillet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer

(2011) H. W. Cheung et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

(2011) T. N. Chonghaile et al.   SCIENCE

Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes

(2011) Maria-Christina Kastrinaki et al.   Current Stem Cell Research & Therapy

Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment

(2011) Govardhanan Nagaiah et al.   Journal of Oncology

Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis

(2010) Conor C. Lynch   BONE

Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity

(2010) David G. DeNardo et al.   CANCER AND METASTASIS REVIEWS

Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment

(2010) N. Chan et al.   CANCER RESEARCH

The COXEN Principle: Translating Signatures of In vitro Chemosensitivity into Tools for Clinical Outcome Prediction and Drug Discovery in Cancer

(2010) S. C. Smith et al.   CANCER RESEARCH

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

(2010) Frits van Rhee et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer and Inflammation: Promise for Biologic Therapy

(2010) Sandra Demaria et al.   JOURNAL OF IMMUNOTHERAPY

Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of β1-integrin in K562 chronic myelogenous leukemia cell line

(2010) Wang Guo-Bao et al.   LEUKEMIA & LYMPHOMA

How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection

(2010) Cristina Scielzo et al.   LEUKEMIA & LYMPHOMA

Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

(2010) E. Weisberg et al.   MOLECULAR CANCER THERAPEUTICS

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

(2010) Douglas W McMillin et al.   NATURE MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment

(2010) K. E. Hung et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Third-Generation Tyrosine Kinase Inhibitors and Beyond

(2010) Alfonso Quintás-Cardama et al.   SEMINARS IN HEMATOLOGY

Examining the Metastatic Niche: Targeting the Microenvironment

(2010) Theresa Guise   SEMINARS IN ONCOLOGY

Effects of Bone Marrow Stromal Cells and Umbilical Cord Blood-Derived Stromal Cells on Daunorubicin-Resistant Residual Jurkat Cells

(2010) X. Liang et al.   TRANSPLANTATION PROCEEDINGS

T Cell Activation

(2009) Jennifer E. Smith-Garvin et al.   Annual Review of Immunology

In vitroanti-myeloma activity of the Aurora kinase inhibitor VE-465

(2009) Joseph M. Negri et al.   BRITISH JOURNAL OF HAEMATOLOGY

Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation

(2009) Ronald R. Gomes et al.   CLINICAL & EXPERIMENTAL METASTASIS

Pathologic Correlates of Primary Central Nervous System Lymphoma Defined in an Orthotopic Xenograft Model

(2009) C. Kadoch et al.   CLINICAL CANCER RESEARCH

Revisiting the seed and soil in cancer metastasis

(2009) Martin Mendoza et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Integrins

(2008) Rita Silva et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine

(2008) A C Dudley et al.   BRITISH JOURNAL OF CANCER

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

(2008) Marta Chesi et al.   CANCER CELL

Development of a Preclinical Model of Spontaneous Human Melanoma Central Nervous System Metastasis

(2008) W. Cruz-Munoz et al.   CANCER RESEARCH

The State of Innovation in Drug Development

(2008) I Kola   CLINICAL PHARMACOLOGY & THERAPEUTICS

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION

Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival

(2008) Bijan Moshaver et al.   LEUKEMIA & LYMPHOMA

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

(2008) Nadine N. Bewry et al.   MOLECULAR CANCER THERAPEUTICS

Sagopilone crosses the blood–brain barrier in vivo to inhibit brain tumor growth and metastases

(2008) Jens Hoffmann et al.   NEURO-ONCOLOGY

Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers

(2008) N. Dumont et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protein therapeutics: a summary and pharmacological classification

(2007) Benjamin Leader et al.   NATURE REVIEWS DRUG DISCOVERY